RxDoctor Payments Data

Phillip Horwitz, MD

Interventional Cardiology · Iowa City, IANPI 1124016787

Payments from drug & device makers

What this record shows

13 manufacturers reported payments, led by Abbott at 37.7% of the total. Reporting peaked in 2024 at $1,497 and has fallen 61.0% since, to $584 in 2025. That places this record below the midpoint for interventional cardiology clinicians in IA, where the typical reported total is $3,872.

$3,336in general payments, 2019–2025

Across 76 payments — averaging $43.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$1K
  • Medtronic$1K
  • Boston Scientific$528
  • Abiomed$114
  • Philips North America LLC$75
  • Acist Medical Systems, Inc.$73
  • plus $126 from 7 others
$2,014,188in research payments, 2019–2025

Across 302 payments — averaging $6669.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Boston Scientific$916K
  • Edwards Lifesciences$655K
  • W. L. Gore & Associates, Inc.$169K
  • Novartis$149K
  • Medtronic$116K
  • Amgen$8K
  • plus $2K from 1 others

What the payments were for

  • Travel & lodging$1,68150%
  • Food & beverage$1,65550%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,336 in reported general payments places this provider in the 40th percentile of 64 interventional cardiology providers in Iowa.

See all interventional cardiology providers in Iowa

Medicare billing

Part B allowed, 2024
$151,481
Medicare patients
561
Services billed
1,021

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin59$34,263
EliquisApixaban35$28,500
Isosorbide Mononitrate ErIsosorbide Mononitrate26$347
Metoprolol Succinate33$343
Furosemide84$341
Ezetimibe12$338
Spironolactone56$311
Bumetanide13$279
Rosuvastatin Calcium18$222
Atorvastatin Calcium29$214
Losartan Potassium34$169
ClopidogrelClopidogrel Bisulfate71$132
Lisinopril14$125
Potassium Chloride19$114
Metoprolol Tartrate44$113

Paid to pharmacies, not to this prescriber.

Other interventional cardiology in Iowa City

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →